News & Updates

Show Multimedia Only

Adalimumab biosimilar performs well in chronic plaque psoriasis treatment

16 Sep 2022

The adalimumab biosimilar BI 695501 has demonstrated equivalent pharmacokinetics to the reference product, with highly comparable efficacy, immunogenicity, and safety in patients with chronic plaque psoriasis, according to data from the phase III VOLTAIRE-X trial.

16 Sep 2022

Core outcome set aims to improve basal cell carcinoma trials

16 Sep 2022

Researchers have recently created a core outcome set for basal cell carcinoma clinical trials.

16 Sep 2022

5-fluorouracil not superior to imiquimod in long-term cSCC prevention

16 Sep 2022

Despite prior evidence of excellent actinic keratosis (AK) destruction efficacy, 5-fluorouracil (5-FU) does not appear to be better than imiquimod in the prevention of cutaneous squamous cell carcinoma (cSCC), reports a recent study.

16 Sep 2022

Older age, itch, pain predict depression in atopic dermatitis

15 Sep 2022

Depressive symptoms are common among adults with atopic dermatitis (AD) severity and may fluctuate over time, reveals a study. Persistent depression is significantly associated with older age, male sex, severe itch, and skin pain, among others.

15 Sep 2022

Monkeypox now a global health emergency

15 Sep 2022 by

The WHO has declared the monkeypox outbreak a global health emergency – the agency’s highest level of alert – following a worldwide upsurge in cases. There are currently 5 deaths tied to the outbreak – Spain has seen two deaths, India has one, while Brazil and Ecuador have one each. As of the latest reports, cases have crossed 38,800 in 80 countries where monkeypox is not endemic.

15 Sep 2022

Roflumilast shows treatment potential for seborrheic dermatitis

15 Sep 2022 by

In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).

15 Sep 2022

Original New Drug Application Approvals by US FDA (01 - 15 September 2022)

15 Sep 2022

New drug applications approved by US FDA as of 01 - 15 September 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

15 Sep 2022